These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 23235432)
1. Intravitreal bevacizumab in the treatment of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension. Lee IJ; Maccheron LJ; Kwan AS J Neuroophthalmol; 2013 Jun; 33(2):155-7. PubMed ID: 23235432 [TBL] [Abstract][Full Text] [Related]
2. Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension. Ozgonul C; Moinuddin O; Munie M; Lee MS; Bhatti MT; Landau K; Van Stavern GP; Mackay DD; Lebas M; DeLott LB; Cornblath WT; Besirli CG J Neuroophthalmol; 2019 Dec; 39(4):451-457. PubMed ID: 30951011 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for peripapillary subretinal neovascular membrane associated to papilledema: a case report. Más AM; Villegas VM; García JM; Acevedo S; Serrano L P R Health Sci J; 2012 Sep; 31(3):148-50. PubMed ID: 23038888 [TBL] [Abstract][Full Text] [Related]
4. Peripapillary choroidal neovascular membrane in a teenage boy: presenting feature of idiopathic intracranial hypertension and resolution with intravitreal bevacizumab. Belliveau MJ; Xing L; Almeida DR; Gale JS; ten Hove MW J Neuroophthalmol; 2013 Mar; 33(1):48-50. PubMed ID: 23403388 [TBL] [Abstract][Full Text] [Related]
5. Successful management of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension with intravitreal ranibizumab. Kumar N; Tigari B; Dogra M; Singh R Indian J Ophthalmol; 2018 Sep; 66(9):1358-1360. PubMed ID: 30127172 [TBL] [Abstract][Full Text] [Related]
6. Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. Figueroa MS; Noval S; Contreras I Br J Ophthalmol; 2008 Sep; 92(9):1244-7. PubMed ID: 18621798 [TBL] [Abstract][Full Text] [Related]
7. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271 [TBL] [Abstract][Full Text] [Related]
8. Subretinal hemorrhage from a peripapillary choroidal neovascular membrane in papilledema caused by idiopathic intracranial hypertension. Sathornsumetee B; Webb A; Hill DL; Newman NJ; Biousse V J Neuroophthalmol; 2006 Sep; 26(3):197-9. PubMed ID: 16966941 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal Ranibizumab Injection in Peripapillary CNVM Related to Idiopathic Intracranial Hypertension. Altan-Yaycioglu R; Canan H; Saygi S J Pediatr Ophthalmol Strabismus; 2017 Apr; 54():e27-e30. PubMed ID: 28453165 [TBL] [Abstract][Full Text] [Related]
10. Idiopathic Peripapillary Subretinal Neovascular Membrane in a Young Woman with Recurrence of the Lesion during Pregnancy after Treatment with Intravitreal Bevacizumab. Al-Gharbi N; Al Abdulsalam O; Al Habash A Middle East Afr J Ophthalmol; 2015; 22(2):245-8. PubMed ID: 25949086 [TBL] [Abstract][Full Text] [Related]
11. Peripapillary neovascular membrane: a rare cause of acute vision loss in pediatric idiopathic intracranial hypertension. Kaeser PF; Borruat FX J AAPOS; 2011 Feb; 15(1):83-6. PubMed ID: 21397812 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri. Jamerson SC; Arunagiri G; Ellis BD; Leys MJ Int Ophthalmol; 2009 Jun; 29(3):183-5. PubMed ID: 18196206 [TBL] [Abstract][Full Text] [Related]
13. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients]. Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650 [TBL] [Abstract][Full Text] [Related]
14. A Young Woman With Headaches and Blurry Vision. Scott NL; Stryjewski TP; Rizzo JF JAMA Ophthalmol; 2017 Jun; 135(6):663-664. PubMed ID: 28301650 [No Abstract] [Full Text] [Related]
15. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926 [TBL] [Abstract][Full Text] [Related]
19. Juxtapapillary neovascular membrane secondary to idiopathic intracranial hypertension treated with intravitreal bevacizumab: A case report. Hernández-Ortega V; Soler-Sanchís MI; Jiménez-Escribano RM; Sanz-López AM Arch Soc Esp Oftalmol; 2016 May; 91(5):250-4. PubMed ID: 26832628 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]